SEC Form 4 · accession 0001000229-16-000153
CORE LABORATORIES N V · CLB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Demshur
Officer — Chief Executive Officer · Director
Period of report
Feb 16, 2016
Accepted (ET)
Feb 16, 2016 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001000229
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Performance SharesF1 | $0.00 | Feb 16, 2016 | A | 52,995 | A | — | — | Common Shares | 52,995 | 52,995 | D |
Explanation of responses
- F1Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, these awards would vest at the end of a three-year performance period that begins on January 1, 2016 and ends on December 31, 2018 (the "Performance Period"). 80% of the restricted performance shares will vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. The remaining 20% of the restricted performance shares will vest only upon the Company's return on invested capital being the highest among the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. For any criterion that is not met, then the respective shares applicable to that criterion shall not vest and shall be forfeited.